Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | High-risk myeloma and MUK Nine

Rakesh Popat • 15 May 2020
Multiple Myeloma

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, gives his perspective on the data submitted to BSH 2020 on the UKMRA OPTIMUM (MUK Nine) which looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN 3:11
Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN
Rakesh Popat • 5 Dec 2025
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM 1:38
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM
Rakesh Popat • 5 Dec 2025
Sequencing bispecific antibodies and CAR-T in multiple myeloma 1:58
Sequencing bispecific antibodies and CAR-T in multiple myeloma
Rakesh Popat • 5 Dec 2025
Treatment goals and preferences in RRMM: patients and physicians 2:29
Treatment goals and preferences in RRMM: patients and physicians
Rakesh Popat • 20 Sep 2025

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals